Global Health & Medicine 2024;6(6):357-362.

HIV-1 protease inhibitors and mechanisms of HIV-1's resistance

Das D

Abstract

Current anti-HIV drugs have significantly improved the prognosis of HIV infected patients so much so that it is now considered a chronic disease, and adherence to medications keeps non-detectable amounts of the virus in the body. However, HIV is still able to generate drug resistance substitutions. Protease inhibitors (PIs) in combination with other classes of anti-HIV drugs constitute an important part of the anti-HIV drug regimen. This article discusses some of the common resistance substitutions against PIs, mechanistic insight on resistance, and potential new inhibitors that can show efficacy against current resistant variants.

KEYWORDS: HIV-1, anti-HIV therapy, protease inhibitors, drug resistance, darunavir

DOI: 10.35772/ghm.2024.01073

Full Text: